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Abstract
Background: The role of Merkel cell polyomavirus (MCV) infection in the etiology of non-melanoma skin cancers,
other than Merkel cell carcinoma, is unclear. Previously, we reported a significant association between seropositivity
to MCV capsid antigen and MCV DNA-positive cutaneous squamous cell carcinoma (SCC). Here we present
associations between SCC and seroreactivity to MCV T-antigen (T-Ag) oncoprotein, as well as MCV DNA detected in
eyebrow hairs.
Findings: A clinic-based case–control study, including 171 SCC cases and 300 controls without skin cancer, was
conducted at Moffitt Cancer Center in Tampa, Florida. Multiplex assays were used to measure serum antibodies
against MCV small and large T-Ag and MCV DNA in both eyebrow hairs and SCC tumors (n = 144). Odds ratios (ORs)
and 95 % confidence intervals (CIs) were estimated using logistic regression to evaluate the associations between
MCV and SCC. No significant association was observed between seroreactivity to MCV full-length large or small
T-Ag and SCC, overall [ORlarge T-Ag = 0.99 (0.48-2.08), ORsmall T-Ag = 0.31 (0.06–1.62)] or when comparing tumor MCV
DNA-positive cases to controls [ORlarge T-Ag = 1.06 (0.38–2.93)]. Only presence of MCV DNA in eyebrow hairs was
significantly associated with MCV DNA-positive SCC [OR = 4.05 (2.01–8.18)].
Conclusion: MCV infection is unlikely to play a direct role in SCC.
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Findings
Introduction
While Merkel cell polyomavirus (MCV) DNA has been
consistently detected in more than 80 % of Merkel cell
carcinoma (MCC) [1–3], the role of MCV in the develop-
ment of other non-melanoma skin cancers, such as cuta-
neous squamous cell carcinoma (SCC), is not established.
Previously, two studies reported presence of MCV DNA
in 0 % of SCC tumors [4, 5], while six other studies
showed MCV DNA in 13–38 % of SCC tumors [6–11].
The one study that examined oncoprotein expression [4]
reported no MCV T-antigen (T-Ag) expression in second-
ary SCCs detected among MCC patients.
In our previous case–control study, MCV DNA was de-
tected in 38 % of 145 SCC tumor tissues and significant
association between seropositivity to MCV capsid antigen
(VP1) and MCV DNA-positive SCC was observed [11].
However, given the high seroprevalence of viral capsid
proteins in cancer free individuals [12], seropositivity to
MCV capsid antigen may not reflect oncogenic viral infec-
tion and additional biomarkers of MCV infection should
be explored.
Truncating mutations in MCV large T-Ag C-terminus
are thought to promote tumor cell proliferation [13].
While the oncogenic role of MCV T-Ag has been estab-
lished in MCC [13, 14], SCC tumors lack the tumor pro-
moting mutations in large T-Ag observed in MCC [7].
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Previous studies examining the role of MCV in SCC
were limited by small sample size and only examined ei-
ther MCV large T-Ag or VP1 protein sequence/expression
in SCC [4, 7, 8, 6, 9]. We expanded our previous case–
control analysis [11] to examine seroreactivity to both
MCV large T-Ag and small T-Ag in association with SCC.
Since serological response to MCV antigens may represent
current and past infection and can possibly be affected
by host factors associated with immune response, we
also examined the association between MCV DNA
present in eyebrow hairs and SCC.
Materials and methods
Study population
The study population has been described in detail previ-
ously [11]. Briefly, a clinic-based case–control study was
conducted at Moffitt Cancer Center, Tampa, Florida in
2007–2009. Cases included newly diagnosed, histologi-
cally confirmed cases of SCC, a majority of which were
immunocompetent [11], and were identified through the
University of South Florida (USF) Dermatology Clinic.
Controls included patients without history of cancer and
had a negative skin cancer screening exam at the USF
Family Medicine Clinic or Moffitt’s cancer screening
clinic. Of the 173 SCC cases and 300 controls included
in the MCV capsid antibody analysis [11], MCV T-Ag
serology results were available for 171 SCC cases and
300 controls. Eyebrow hair samples were available for
169 SCC cases and 292 controls. All study participants
completed a comprehensive questionnaire on demo-
graphics, lifestyle and skin cancer risk factors.
Ethics, consent and permissions
All participants provided written informed consent, and
the study protocol was approved by the Institutional
Review Board at USF.
MCV serology
Serum antibodies (IgG) to small T-Ag, full-length large T-
Ag, large T-Ag exon 1 and large T-Ag exon 2 of MCV
(isolate 344) were measured using a fluorescent bead-
based multiplex assay, as described previously [15, 11, 16].
Briefly, seroreactivity to MCV T-Ag was expressed as me-
dian fluorescence intensity (MFI). The cut-offs for sero-
positivity were determined using an independent
reference sample of 42 MCC patients (200 MFI for small
T-Ag, 200 MFI for large T-Ag exon 1,400 MFI for large
T-Ag exon 2 and 400 MFI for full-length large T-Ag).
MCV DNA measurement in SCC tumor tissues
As described previously, MCV DNA from eyebrow hairs
and fresh frozen SCC tumor tissue was detected using a
highly sensitive and specific assay which combines multi-
plex polymerase chain reaction (PCR) and bead-based
Luminex technology [11, 17]. MCV viral load (absolute
copy number per sample) in SCC tumor tissue was deter-
mined using a multiplex quantitative real-time PCR
targeting the N-terminus and C-terminus of the MCV T-
antigen sequence [18]. The ratio of N-terminus to C-
terminus copy numbers of MCV DNA was determined to
examine the presence of C-terminus deletions. Two sam-
ples of formalin fixed paraffin embedded MCC tumor
tissues were analyzed as positive controls. Data on both
MCV T-Ag serology and MCV tumor DNA were available
from 144 SCC cases, while data on MCV DNA in eyebrow
hair and MCV DNA in SCC tumor were available from
141 SCC cases.
Statistical analysis
Associations between MCV T-Ag seropositivity, MCV
DNA in eyebrow hairs and SCC were estimated by odds
ratios (OR) and 95 % confidence intervals (CI) calculated
using logistic regression with adjustment for age and
gender. Odds ratios were calculated separately for MCV
DNA-positive SCC cases and MCV DNA-negative SCC
cases using multinomial logistic regression, also adjust-
ing for age and gender. Analyses were conducted using
SAS software, version 9.3 (SAS institute Inc., Cary,
North Carolina) and R software, version 2.15.1 [19].
Results
Demographic characteristics of the study population and
factors associated with SCC have been described previously
[11]. Cases (mean age = 64.4, standard deviation = 9.9)
were significantly older compared to controls (mean
age = 55.4, standard deviation = 11.7, p value = <0.0001),
and were more likely to be males (65.9 %) compared to
controls (38.0 %, P value = <0.0001) [11]. As seen in
Table 1, 0.3–1 % of controls and 0–1.2 % of SCC cases
were seropositive to MCV T-Ags based on MFI cut-offs
determined using a reference sample of MCC cases.
Due to the small number of seropositive cases and con-
trols, robust statistical analyses to examine age-adjusted
association of MCV seropositivity with SCC could not
be conducted. Hence, a less stringent cut-off of >50
MFI for seropositivity was used and no significant asso-
ciations between seropositivity to any of the MCV anti-
gens and SCC were observed, after adjusting for age
and gender (Table 1). MCV DNA was present in eye-
brow hairs for 37.3 % of controls and 48.5 % of SCC
cases, a difference that was not statistically significant
(Table 1).
When analyses were stratified by the presence of MCV
DNA in SCC tumors, no associations were observed with
seroreactivity to MCV large T-Ag (Table 2). A statistically
significant four-fold association was observed between
the presence of MCV DNA in eyebrow hairs and MCV
DNA-positive SCC versus controls (OR = 4.05, 95 % CI
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= 2.01–8.18), while no association was observed with
MCV DNA-negative SCC versus controls (OR = 0.58,
95 % CI = 0.34–1.01) (Table 2).
Overall, MCV copy numbers were lower for SCC com-
pared to the two MCC tumor samples analyzed (Fig. 1).
The ratio of C- to N-terminus of all SCC samples was close
to 1.0, indicating the presence of full-length large T-Ag.
Discussion
In this clinic based case–control study, no significant as-
sociation was observed between seropositivity to MCV
T-Ag and SCC, overall or after stratifying by MCV DNA
status in SCC tumor tissues. Interestingly, a greater than
four-fold significant association was observed between
MCV DNA positivity in eyebrow hairs and MCV DNA
positive-SCC, although it should be noted that MCV
viral DNA load was low in SCC tumors, with all exhibit-
ing less than one viral copy per tumor cell.
Previously, in the same study population, we observed
a greater than two-fold association between MCV DNA-
positive SCC and seropositivity to the MCV capsid anti-
gen, VP1 [11]. However, in our previous study [11],
73.3 % controls and 80.9 % SCC cases were seropositive
for VP1. In contrast, we report here <2 % of cases and
controls were seropositive for MCV large T-Ag using
the cut-off derived from MCC patients. As discussed
previously [16], unlike viral capsid proteins, MCV T-Ags
are located within the nucleus and are less likely to
stimulate a serological response unless the T-Ag is
expressed in tumors. While T-Ag DNA sequences have
been detected in MCV-positive SCC tumor tissues [6],
their expression has not been observed in SCC tumor
tissues arising in MCC patients [4] or in immunocompe-
tent SCC cases [7]. This could explain the lower sero-
prevalence of MCV T-Ag observed among SCC cases
compared to that of viral capsid antigens, as well as the
Table 2 Associations between Merkel cell polyomavirus and cutaneous squamous cell carcinoma by tumor MCV DNA status
Controls
(N = 300)
MCV tumor-negative SCC cases
(N = 89)
MCV tumor-positive SCC cases
(N = 55)
p-value
MCV biomarker n (%) n (%) OR (95 % CI)* n (%) OR (95 % CI)*
Seropositivity to MCV T-Ag (>50 MFI)
MCV small T-Ag 7 (2.3) 2 (2.2) 0.63 (0.12–3.32) 0 (0) Could not be estimated 0.862
MCV large T-Ag exon 1 3 (1.0) 1 (1.1) 1.11 (0.11–11.61) 0 (0) Could not be estimated 0.996
MCV large T-Ag exon 2 18 (6) 10 (11.2) 1.50 (0.63–3.53) 5 (9.1) 1.06 (0.35–3.2) 0.640
MCV large T-Ag 22 (7.3) 9 (10.1) 1.10 (0.47–2.6) 6 (10.9) 1.06 (0.38–2.93) 0.975
Controls MCV-DNA negative SCC cases MCV-DNA positive SCC cases p-value
(n = 292) (n = 86) (n = 55)
n (%) OR (95 % CI)* n (%) OR (95 % CI)*
MCV DNA present in eyebrow hairs 109 (37.3) 26 (30.2) 0.58 (0.34–1.01) 42 (76.4) 4.05 (2.01–8.18) 1.06 × 10 −6
MCV Merkel cell polyomavirus, SCC cutaneous squamous cell carcinoma. * Odds ratios (OR) and 95 % confidence intervals (CI) calculated separately SCC cases with
or without MCV DNA in their tumors using polynomial logistic regression, adjusting for age and gender
Table 1 Associations between Merkel cell polyomavirus and cutaneous squamous cell carcinoma
MCV biomarker Controls SCC Cases Controls SCC Cases OR (95 % CI) p-value
N = 300 N = 171 N = 300 N = 171
n (%) n (%) n (%) n (%)
Seropositivity to MCV T-Ag Cut points based on reference sample* Cut point of > 50 MFI
MCV small T 1 (0.3) 0 (0) 7 (2.3) 2 (1.2) 0.31 (0.06–1.62) 0.164
MCV large T exon 1 2 (0.7) 0 (0) 3 (1) 1 (0.6) 0.56 (0.05–5.93) 0.633
MCV large T exon 2 2 (0.7) 1 (0.6) 18 (6) 16 (9.4) 1.22 (0.57–2.62) 0.611
MCV large T 3 (1.0) 2 (1.2) 22 (7.3) 16 (9.4) 0.99 (0.48–2.08) 0.988
Controls (n = 292) Cases (n = 169) OR (95 % CI) p-value
n(%) n(%)
Presence of MCV DNA in eyebrow hairs 109 (37.3) 82 (48.5) 1.17 (0.76–1.78) 0.478
MCV Merkel cell polyomavirus, SCC cutaneous squamous cell carcinoma. *MFI cutoff for seropositivity based on MCC patients: 200 for small T, 200 for large T exon
1,400 for large T exon 2 and 400 for large T. Odds ratios (OR) and Wald 95 % confidence intervals (CI) calculated using alternative cutoff of >50 MFI and logistic
regression, adjusting for age and gender
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lower seroprevalence of MCV T-Ag in SCC cases com-
pared to that reported among MCC cases [16].
The lack of an association between seropositivity to
MCV T-Ag and SCC, and low viral DNA load in SCC
tumors, suggest that MCV is not directly involved in the
development of SCC. Further, the ratio of N-terminus
to C-terminus of MCV T-Ag was close to 1.0 in MCV
DNA-positive SCC (Fig. 1), indicating a lack of the
tumor-promoting, signature T-Ag mutations described
for MCC. Despite the lack of evidence for a causal role
of MCV in SCC, an indirect role of MCV cannot be
ruled out. In the present study, a four-fold association
was observed between the presence of MCV DNA in eye-
brow hairs and MCV DNA-positive SCC. This strong as-
sociation, consistent with our previous report of a positive
association between MCV seropositivity to capsid antigen
and MCV DNA-positive SCC [11], suggests MCV may be
a marker of an unknown immunological factor associated
with SCC, acting either synergistically with or independ-
ently of MCV infection. However, in this retrospective
case–control study, it is not possible to distinguish be-
tween immunological factors that predispose to SCC ver-
sus those that result from the presence of the cancer itself.
A prospective study examining MCV infection in multiple
biospecimens prior to the onset of SCC and markers of
immune function is needed to elucidate the precise role of
MCV in SCC.
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